Hybridoma technology is a well-established method for generating monoclonal antibodies (mAB), but various scientific and organizational challenges persist. Laborious and resource-intensive processes, low titers, and complex assays mean that scientists have to streamline every step, simplify handoffs, and track large amounts of complex data. Robust data management is key to effectively leveraging this antibody technology.
This application note provides:
- How Benchling’s capabilities can power hybridoma technology and help scientists manage the entire process from antigen design to antibody characterization